journal article·2004-11-01

Polymorphism in Piroxicam

Agam R. Sheth, Simon Bates, Francis X. Muller, David J. W. Grant

Crystal Growth & Design· Volume 4· Issue 6
Publisher page

Abstract

Piroxciam is a polymorphic drug. However, reports on the number and nomenclature of the polymorphs of piroxicam and the complete hydrogen-bonding patterns of piroxicam molecules in the crystal forms are in conflict and are sources of confusion, which we attempt to clarify. The difference in energy of the two polymorphs, I and II, of piroxicam arises predominantly from the difference between their lattice energies, rather than between their conformational energies. The detailed hydrogen-bonding networks of the two polymorphs are described and compared. Despite stabilization of the polymorphs by hydrogen bonds, a loss of polymorphic memory was observed upon cryogrinding the two polymorphs, leading to differences in recrystallization behavior between amorphous piroxicam prepared from polymorphs I and II.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Weaver-Densford Hall, 308 Harvard Street Southeast, Minneapolis, Minnesota 55455-0343, SSCI Inc., 3065 Kent Avenue, West Lafayette, Indiana 47906-1076, and GlaxoSmithKline Pharmaceuticals, P.O. Box 1539, 709 Swedeland Road, King of Prussia, Pennsylvania 19406-0939

References (27)

Show source-provided references
1. The Merck Index, 13th ed.; Merck & Co., Inc. Whitehouse Station, NJ, 2001; p 7588.
2. (b) Majerus, P. W.; Broze, G. J.; Miletich, J. P.; Tollefsen, D. M.Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Eds.; McGraw-Hill: New York, 1996; pp 640−641.
3. Mihalic M. · Acta Pharm. Jugosl. · 1982 · 32 · 20
4. Kozjek F. · Acta Pharm. Jugosl. · 1985 · 35 · 281
5. Mihalic M. · Anal. Profiles Drug Subst. · 1986 · 15 · 531
6. Vrecer F. · Int. J. Pharm. · 1991 · 68 · 41
7. Csoka G. · Drug. Dev. Ind. Pharm. · 1999 · 25 · 81610.1081/DDC-100102243 ↗
8. Kojic-Prodic B. · Acta Crystallogr. · 1982 · 38 · 295110.1107/S0567740882010462 ↗
9. Reck G. · Pharmazie · 1988 · 43 · 481
10. Cambridge Crystallographic Data Center · Acta Crystallogr. · 2002 · 58 · 388
11. Version 2.2; Cambridge Crystallographic Data Center: 2003.
12. SSCI Indexing Program, Version 1.3.4; SSCI, Inc. 2004.
13. Vrecer F. · Int. J. Pharm. · 2003 · 256 · 1510.1016/S0378-5173(03)00057-7 ↗
14. Reck G. · Pharmazie · 1990 · 45 · 259
15. Frisch M. J. · 2003
16. Becke A. D · J. Chem. Phys. · 1993 · 98 · 565210.1063/1.464913 ↗
17. Bernstein J. · 2002
18. Yu L. · J. Am. Chem. Soc. · 2000 · 122 · 591
19. Taddei P. · Biopolymers (Biospectroscopy) · 2001 · 62 · 7810.1002/1097-0282(2001)62:1<68::AID-BIP80>3.0.CO;2-X ↗
20. Janik M. · J. Crystallogr. Spectrosc. Res. · 1991 · 21 · 52210.1007/BF01160669 ↗
21. Bernstein J · Acta Crystallogr. · 1979 · 35 · 36610.1107/S056774087900354X ↗
22. Etter M. C · Isr. J. Chem. · 1985 · 25 · 319
23. Redenti E. · Int. J. Pharm. · 1996 · 129 · 29410.1016/0378-5173(95)04357-8 ↗
24. The United States Pharmacopoeia XXVII, USP27/NF22, 27th revision;
25. Crowley K. J. · J. Pharm. Sci. · 2002 · 91 · 50710.1002/jps.10028 ↗
26. Lutteroti L.
27. Billinge S. J. L. · 1998